

(19)



JAPANESE PATENT OFFICE

PATENT ABSTRACTS OF JAPAN

(11) Publication number: **06092853 A**

(43) Date of publication of application: **05.04.94**

(51) Int. Cl

A61K 31/44
A61K 9/08
A61K 9/14

(21) Application number: **05160925**

(22) Date of filing: **30.06.93**

(30) Priority: **28.07.92 JP 04201203**

(71) Applicant: **FUJISAWA PHARMACEUT CO LTD**
YOSHITOMI PHARMACEUT IND
LTD

(72) Inventor: **NAKANISHI SHIGEO**
TOMINAGA TETSUO
YAMANAKA IWAO
HIGO TAKASHI
SHIBATA TOSHIYUKI

(54) **PARENTERAL INJECTION AND KIT THEREFOR**

(57) Abstract:

PURPOSE: To obtain a parenteral injection of a benzimidazole-based compound or its salt, capable of being readily formulated into a pharmaceutical preparation, reduced in side effects such as hemolysis with hardly any local irritancy.

CONSTITUTION: The objective parenteral injection at pH 9.5-11.5 is composed of a 2-[(2-pyridyl)methylsulfinyl]benzimidazole-based compound having antiulcer action (e.g. omeprazole) or its salt and an aqueous solvent without containing a nonaqueous solvent. This parental injection is prepared by dissolving the benzimidazole-based compound, preferably its salt, together with a strong alkaline

substance, in water, etc., for the parenteral injection, regulating the pH to 10.5-12.5, preferably 11-12, preparing an alkaline aqueous solution, then filling the prepared aqueous solution in a vial, suitably replacing the atmosphere in the vial with nitrogen gas, subsequently freeze-drying the aqueous solution according to a well-known method and dissolving the freeze-dried substance in an aqueous solvent (e.g. a physiological saline solution of distilled water for the parenteral injection) without containing a nonaqueous solvent in use. The need for addition of the nonaqueous solvent for enhancing the solubility of the compound which is the active ingredient is eliminated to cancel side effects of the nonaqueous solvent.

COPYRIGHT: (C)1994,JPO&Japio

BEST AVAILABLE COPY